O	0	8	p18Ink4c	p18Ink4c	NN	B-NP
O	8	9	,	,	,	O
O	10	13	but	but	CC	O
O	14	17	not	not	RB	O
O	18	25	p27Kip1	p27Kip1	NN	B-NP
O	25	26	,	,	,	O
O	27	39	collaborates	collaborate	VBZ	B-VP
O	40	44	with	with	IN	B-PP
O	45	49	Men1	Men1	NN	B-NP
O	50	52	to	to	TO	B-VP
O	53	61	suppress	suppress	VB	I-VP
B-Cancer	62	76	neuroendocrine	neuroendocrine	JJ	B-NP
I-Cancer	77	82	organ	organ	NN	I-NP
I-Cancer	83	89	tumors	tumor	NNS	I-NP
O	89	90	.	.	.	O

O	92	98	Mutant	Mutant	JJ	B-NP
O	99	103	mice	mouse	NNS	I-NP
O	104	111	lacking	lack	VBG	B-VP
O	112	116	both	both	CC	O
O	117	123	cyclin	cyclin	NN	B-NP
O	123	124	-	-	HYPH	B-NP
O	124	133	dependent	dependent	JJ	I-NP
O	134	140	kinase	kinase	NN	I-NP
O	141	142	(	(	(	O
O	142	145	CDK	CDK	NN	B-NP
O	145	146	)	)	)	O
O	147	157	inhibitors	inhibitor	NNS	B-NP
O	158	161	p18	p18	NN	I-NP
O	161	162	(	(	(	O
O	162	167	Ink4c	Ink4c	NN	B-NP
O	167	168	)	)	)	O
O	169	172	and	and	CC	O
O	173	176	p27	p27	NN	B-NP
O	176	177	(	(	(	O
O	177	181	Kip1	Kip1	NN	B-NP
O	181	182	)	)	)	O
O	183	190	develop	develop	VBP	B-VP
O	191	192	a	a	DT	B-NP
B-Cancer	193	198	tumor	tumor	NN	I-NP
O	199	207	spectrum	spectrum	NN	I-NP
O	208	219	reminiscent	reminiscent	NN	I-NP
O	220	222	of	of	IN	B-PP
O	223	228	human	human	JJ	B-NP
B-Cancer	229	237	multiple	multiple	JJ	I-NP
I-Cancer	238	247	endocrine	endocrine	JJ	I-NP
I-Cancer	248	257	neoplasia	neoplasia	NN	I-NP
O	258	259	(	(	(	O
B-Cancer	259	262	MEN	MEN	NN	B-NP
O	262	263	)	)	)	O
O	264	273	syndromes	syndrome	NNS	B-NP
O	273	274	.	.	.	O

O	275	277	To	To	TO	B-VP
O	278	287	determine	determine	VB	I-VP
O	288	291	how	how	WRB	B-ADVP
O	292	295	p18	p18	NN	B-NP
O	296	299	and	and	CC	I-NP
O	300	303	p27	p27	NN	I-NP
O	304	315	genetically	genetically	RB	B-ADVP
O	316	324	interact	interact	VBP	B-VP
O	325	329	with	with	IN	B-PP
O	330	334	Men1	Men1	NN	B-NP
O	334	335	,	,	,	O
O	336	339	the	the	DT	B-NP
B-Cancer	340	345	tumor	tumor	NN	I-NP
O	346	356	suppressor	suppressor	NN	I-NP
O	357	361	gene	gene	NN	I-NP
O	362	369	mutated	mutate	VBN	B-VP
O	370	372	in	in	IN	B-PP
O	373	381	familial	familial	JJ	B-NP
B-Cancer	382	386	MEN1	MEN1	NN	I-NP
O	386	387	,	,	,	O
O	388	390	we	we	PRP	B-NP
O	391	404	characterized	characterize	VBD	B-VP
O	405	408	p18	p18	NN	B-NP
O	408	409	-	-	HYPH	B-NP
O	409	413	Men1	Men1	NN	I-NP
O	414	417	and	and	CC	I-NP
O	418	421	p27	p27	NN	I-NP
O	421	422	-	-	HYPH	B-NP
O	422	426	Men1	Men1	NN	I-NP
O	427	433	double	double	JJ	I-NP
O	434	440	mutant	mutant	JJ	I-NP
O	441	445	mice	mouse	NNS	I-NP
O	445	446	.	.	.	O

O	447	455	Compared	Compare	VBN	B-PP
O	456	460	with	with	IN	B-PP
O	461	466	their	their	PRP$	B-NP
O	467	480	corresponding	correspond	VBG	I-NP
O	481	487	single	single	JJ	I-NP
O	488	494	mutant	mutant	JJ	I-NP
O	495	506	littermates	littermate	NNS	I-NP
O	506	507	,	,	,	O
O	508	511	the	the	DT	B-NP
O	512	515	p18	p18	NN	I-NP
O	515	516	(	(	(	O
O	516	517	-	-	SYM	B-NP
O	517	518	/	/	SYM	O
O	518	519	-	-	SYM	O
O	519	520	)	)	)	O
O	520	521	;	;	:	O
O	522	526	Men1	Men1	NN	B-NP
O	526	527	(	(	(	O
O	527	528	+	+	SYM	O
O	528	529	/	/	SYM	O
O	529	530	-	-	SYM	O
O	530	531	)	)	)	O
O	532	536	mice	mouse	NNS	B-NP
O	537	544	develop	develop	VBP	B-VP
B-Cancer	545	551	tumors	tumor	NNS	B-NP
O	552	554	at	at	IN	B-PP
O	555	557	an	an	DT	B-NP
O	558	569	accelerated	accelerate	VBN	I-NP
O	570	574	rate	rate	NN	I-NP
O	575	578	and	and	CC	B-PP
O	579	583	with	with	IN	B-PP
O	584	586	an	an	DT	B-NP
O	587	596	increased	increase	VBN	I-NP
O	597	606	incidence	incidence	NN	I-NP
O	607	609	in	in	IN	B-PP
O	610	613	the	the	DT	B-NP
B-Organ	614	623	pituitary	pituitary	NN	I-NP
O	623	624	,	,	,	O
B-Organ	625	632	thyroid	thyroid	NN	B-NP
O	632	633	,	,	,	O
B-Organ	634	645	parathyroid	parathyroid	NN	B-NP
O	645	646	,	,	,	O
O	647	650	and	and	CC	O
B-Organ	651	659	pancreas	pancreas	NN	B-NP
O	659	660	.	.	.	O

O	661	663	In	In	IN	B-PP
O	664	667	the	the	DT	B-NP
B-Organ	668	677	pituitary	pituitary	JJ	I-NP
O	678	681	and	and	CC	I-NP
B-Multi-tissue_structure	682	692	pancreatic	pancreatic	JJ	I-NP
I-Multi-tissue_structure	693	699	islets	islet	NNS	I-NP
O	699	700	,	,	,	O
O	701	716	phosphorylation	phosphorylation	NN	B-NP
O	717	719	of	of	IN	B-PP
O	720	723	the	the	DT	B-NP
O	724	738	retinoblastoma	retinoblastoma	NN	I-NP
O	739	740	(	(	(	O
O	740	742	Rb	Rb	NN	B-NP
O	742	743	)	)	)	O
O	744	751	protein	protein	NN	B-NP
O	752	754	at	at	IN	B-PP
O	755	759	both	both	CC	O
O	760	764	CDK2	CDK2	NN	B-NP
O	765	768	and	and	CC	I-NP
O	769	773	CDK4	CDK4	NN	I-NP
O	773	774	/	/	SYM	B-NP
O	774	775	6	6	CD	B-NP
O	776	781	sites	site	NNS	I-NP
O	782	785	was	be	VBD	B-VP
O	786	795	increased	increase	VBN	I-VP
O	796	798	in	in	IN	B-PP
B-Cell	799	802	p18	p18	NN	B-NP
I-Cell	802	803	(	(	(	O
I-Cell	803	804	-	-	SYM	B-NP
I-Cell	804	805	/	/	SYM	B-NP
I-Cell	805	806	-	-	SYM	B-NP
I-Cell	806	807	)	)	)	O
I-Cell	808	811	and	and	CC	O
I-Cell	812	816	Men1	Men1	NN	B-NP
I-Cell	816	817	(	(	(	O
I-Cell	817	818	+	+	SYM	O
I-Cell	818	819	/	/	SYM	O
I-Cell	819	820	-	-	SYM	O
I-Cell	820	821	)	)	)	O
I-Cell	822	827	cells	cell	NNS	B-NP
O	828	831	and	and	CC	O
O	832	835	was	be	VBD	B-VP
O	836	843	further	further	RBR	I-VP
O	844	853	increased	increase	VBN	I-VP
O	854	856	in	in	IN	B-PP
B-Cell	857	860	p18	p18	NN	B-NP
I-Cell	860	861	(	(	(	O
I-Cell	861	862	-	-	SYM	B-NP
I-Cell	862	863	/	/	SYM	O
I-Cell	863	864	-	-	SYM	O
I-Cell	864	865	)	)	)	O
I-Cell	865	866	;	;	:	O
I-Cell	867	871	Men1	Men1	NN	B-NP
I-Cell	871	872	(	(	(	O
I-Cell	872	873	+	+	SYM	O
I-Cell	873	874	/	/	SYM	O
I-Cell	874	875	-	-	SYM	O
I-Cell	875	876	)	)	)	O
I-Cell	877	882	cells	cell	NNS	B-NP
O	882	883	.	.	.	O

O	884	887	The	The	DT	B-NP
O	888	897	remaining	remain	VBG	I-NP
O	898	902	wild	wild	JJ	I-NP
O	902	903	-	-	HYPH	I-NP
O	903	907	type	type	NN	I-NP
O	908	912	Men1	Men1	NN	I-NP
O	913	919	allele	allele	NN	I-NP
O	920	923	was	be	VBD	B-VP
O	924	928	lost	lose	VBN	I-VP
O	929	931	in	in	IN	B-PP
O	932	936	most	most	JJS	B-NP
B-Cancer	937	943	tumors	tumor	NNS	I-NP
O	944	948	from	from	IN	B-PP
O	949	953	Men1	Men1	NN	B-NP
O	953	954	(	(	(	O
O	954	955	+	+	SYM	O
O	955	956	/	/	SYM	O
O	956	957	-	-	SYM	O
O	957	958	)	)	)	O
O	959	963	mice	mouse	NNS	B-NP
O	964	967	but	but	CC	O
O	968	971	was	be	VBD	B-VP
O	972	980	retained	retain	VBN	I-VP
O	981	983	in	in	IN	B-PP
O	984	988	most	most	JJS	B-NP
B-Cancer	989	995	tumors	tumor	NNS	I-NP
O	996	1000	from	from	IN	B-PP
O	1001	1004	p18	p18	NN	B-NP
O	1004	1005	(	(	(	O
O	1005	1006	-	-	SYM	B-NP
O	1006	1007	/	/	SYM	O
O	1007	1008	-	-	SYM	O
O	1008	1009	)	)	)	O
O	1009	1010	;	;	:	O
O	1011	1015	Men1	Men1	NN	B-NP
O	1015	1016	(	(	(	O
O	1016	1017	+	+	SYM	O
O	1017	1018	/	/	SYM	O
O	1018	1019	-	-	SYM	O
O	1019	1020	)	)	)	O
O	1021	1025	mice	mouse	NNS	B-NP
O	1025	1026	.	.	.	O

O	1027	1035	Combined	Combine	VBN	B-NP
O	1036	1045	mutations	mutation	NNS	I-NP
O	1046	1048	of	of	IN	B-PP
O	1049	1052	p27	p27	NN	B-NP
O	1052	1053	(	(	(	O
O	1053	1054	-	-	SYM	B-NP
O	1054	1055	/	/	SYM	B-NP
O	1055	1056	-	-	SYM	B-NP
O	1056	1057	)	)	)	O
O	1058	1061	and	and	CC	O
O	1062	1066	Men1	Men1	NN	B-NP
O	1066	1067	(	(	(	O
O	1067	1068	+	+	SYM	B-NP
O	1068	1069	/	/	SYM	O
O	1069	1070	-	-	SYM	B-NP
O	1070	1071	)	)	)	O
O	1071	1072	,	,	,	O
O	1073	1075	in	in	IN	B-PP
O	1076	1084	contrast	contrast	NN	B-NP
O	1084	1085	,	,	,	O
O	1086	1089	did	do	VBD	B-VP
O	1090	1093	not	not	RB	I-VP
O	1094	1101	exhibit	exhibit	VB	I-VP
O	1102	1112	noticeable	noticeable	JJ	B-NP
O	1113	1124	synergistic	synergistic	JJ	I-NP
O	1125	1136	stimulation	stimulation	NN	I-NP
O	1137	1139	of	of	IN	B-PP
O	1140	1142	Rb	Rb	NN	B-NP
O	1143	1149	kinase	kinase	NN	I-NP
O	1150	1158	activity	activity	NN	I-NP
O	1158	1159	,	,	,	O
B-Cell	1160	1164	cell	cell	NN	B-NP
O	1165	1178	proliferation	proliferation	NN	I-NP
O	1178	1179	,	,	,	O
O	1180	1183	and	and	CC	O
B-Cancer	1184	1189	tumor	tumor	NN	B-NP
O	1190	1196	growth	growth	NN	I-NP
O	1196	1197	.	.	.	O

O	1198	1203	These	These	DT	B-NP
O	1204	1211	results	result	NNS	I-NP
O	1212	1223	demonstrate	demonstrate	VBP	B-VP
O	1224	1228	that	that	IN	B-SBAR
O	1229	1239	functional	functional	JJ	B-NP
O	1240	1253	collaboration	collaboration	NN	I-NP
O	1254	1260	exists	exist	VBZ	B-VP
O	1261	1268	between	between	IN	B-PP
O	1269	1272	p18	p18	NN	B-NP
O	1273	1276	and	and	CC	I-NP
O	1277	1281	Men1	Men1	NN	I-NP
O	1282	1285	and	and	CC	O
O	1286	1293	suggest	suggest	VBP	B-VP
O	1294	1298	that	that	IN	B-SBAR
O	1299	1303	Men1	Men1	NN	B-NP
O	1304	1307	may	may	MD	B-VP
O	1308	1316	regulate	regulate	VB	I-VP
O	1317	1327	additional	additional	JJ	B-NP
O	1328	1334	factor	factor	NN	I-NP
O	1334	1335	(	(	(	I-NP
O	1335	1336	s	s	NNS	I-NP
O	1336	1337	)	)	)	O
O	1338	1342	that	that	WDT	B-NP
O	1343	1351	interact	interact	VBP	B-VP
O	1352	1356	with	with	IN	B-PP
O	1357	1360	p18	p18	NN	B-NP
O	1361	1364	and	and	CC	I-NP
O	1365	1368	p27	p27	NN	I-NP
O	1369	1380	differently	differently	RB	B-ADVP
O	1380	1381	.	.	.	O

